Akston Begins Trials For Room Temperature Covid Shot As Next-Generation Vaccine Race Heats Up
Published
Nov 20 2021 at 8:41 PM GMT
Key
Points
Points
- Massachusetts-based Akston Biosciences dosed the first participants in a Phase 2/3 study to test its Covid-19 vaccine, which is stable for at least six months at room temperature.
-
Posted in Business
Trending
Stats
- Published Nov 20, 2021 8:41 PM GMT